Why Did the European Medicines Agency Reject a Drug Slowing Down Alzheimer’s Disease
The European Medicines Agency (EMA) has announced its decision to reject the marketing authorization of the drug "Leqembi" for the treatment of Alzheimer's disease, citing safety concerns and severe side effects. In a statement, the agency…
اقرأ أكثر...
اقرأ أكثر...